Rizvi Qasim 4
4 · Kiniksa Pharmaceuticals, Ltd. · Filed Jan 5, 2021
Insider Transaction Report
Form 4
Rizvi Qasim
Chief Commercial Officer
Transactions
- Tax Payment
Class A Common Share
2020-12-31$17.67/sh−2,161$38,185→ 5,176 total - Exercise/Conversion
Class A Common Share
2020-12-31+7,337→ 7,337 total - Exercise/Conversion
Restricted Share Unit
2020-12-31−7,337→ 0 total→ Class A Common Share (7,337 underlying)
Footnotes (2)
- [F1]Each Restricted Share Unit represents a contingent right to receive one Class A Common Share of the Issuer.
- [F2]The RSU will vest in a single installment on December 31, 2020, subject to the Reporting Person's continuous employment or service to the Issuer or any of its subsidiaries on the vesting date; there is no expiration date for the RSU.